KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Gross Profit (2016 - 2025)

Boston Scientific's Gross Profit history spans 17 years, with the latest figure at $3.7 billion for Q4 2025.

  • For Q4 2025, Gross Profit rose 18.84% year-over-year to $3.7 billion; the TTM value through Dec 2025 reached $13.9 billion, up 20.57%, while the annual FY2025 figure was $13.9 billion, 20.57% up from the prior year.
  • Gross Profit for Q4 2025 was $3.7 billion at Boston Scientific, up from $3.5 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $3.7 billion in Q4 2025 and bottomed at $1.9 billion in Q1 2021.
  • The 5-year median for Gross Profit is $2.5 billion (2023), against an average of $2.6 billion.
  • The largest annual shift saw Gross Profit skyrocketed 75.91% in 2021 before it grew 3.57% in 2022.
  • A 5-year view of Gross Profit shows it stood at $2.2 billion in 2021, then grew by 3.57% to $2.2 billion in 2022, then increased by 15.55% to $2.6 billion in 2023, then increased by 20.01% to $3.1 billion in 2024, then rose by 18.84% to $3.7 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Gross Profit are $3.7 billion (Q4 2025), $3.5 billion (Q3 2025), and $3.4 billion (Q2 2025).